ThesaurusId, Title
8514,Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Head and Neck
24,RESULTS
31,Page 1
Not set,Head and Neck Squamous Cell Carcinoma (HNSCC)
33,p16 Expression (by immunohistochemistry) as a Surrogate for Transcriptionally Active High-Risk HPV
34,Negative (<50% diffuse and strong nuclear and cytoplasmic staining)
35,Equivocal (<70% but >50% diffuse and strong nuclear and cytoplasmic staining)
36,Positive (>70% diffuse and strong nuclear and cytoplasmic staining)
37,Indeterminate
38,Indeterminate (explain):
39,HPV-DNA (by in situ hybridization [ISH])
40,Negative (no signal)
41,Positive
42,Indeterminate
43,Positive
45,Punctate
46,Diffuse
47,Subtype(s)
48,Indeterminate (explain):
49,Subtype(s) (if available):
50,HPV E6/E7 mRNA (by ISH)
51,Negative (no signal)
52,Positive (cytoplasmic and/or nuclear signals)
53,Indeterminate
54,Subtype(s) (if available):
55,Indeterminate (explain):
56,HPV-DNA (by polymerase chain reaction [PCR])
57,Negative (no signal)
58,Positive
59,Indeterminate
60,Subtype(s) (if available):
61,Indeterminate (explain):
62,HPV E6/E7 mRNA (by reverse transcriptase polymerase chain reaction [RT-PCR])
63,Negative (no signal)
64,Positive
65,Indeterminate
66,Subtype(s) (if available):
67,Indeterminate (explain):
Not set,Epstein-Barr Virus (EBV) Testing
68,EBV Early mRNA (EBER) (by ISH)
69,Negative (no signal)
70,Positive(nuclear signal)
71,Indeterminate
72,Indeterminate (explain):
Not set,NUT Midline Carcinoma
73,NUT Expression (by immunohistochemistry [IHC])
74,Negative
75,Positive
76,Indeterminate
78,Indeterminate (explain):
79,NUT Rearrangements (by Fluorescence ISH [FISH])
80,No NUT rearrangement detected
81,NUT rearrangement detected
82,Percentage of positive cells (%):
83,Percentage of positive cells with classic rearrangement (if applicable) (%):
84,Percentage of positive cells with complex rearrangement (if applicable) (%):
85,BRD4-NUT Fusion (by RT-PCR)
86,No BRD4-NUT fusions detected
87,BRD4-NUT fusions detected
89,Other NUT Fusion (by RT-PCR)
90,No NUT translocation detected
91,NUT translocation detected
95,Fusion partner:
Not set,Salivary Gland Carcinoma
97,EWSR1 Rearrangements (by FISH)
98,No EWSR1 rearrangement detected
99,EWSR1 rearrangement detected
100,Indeterminate
101,Percentage of positive cells (%):
102,Percentage of positive cells with classic rearrangement (if applicable) (%):
103,Percentage of positive cells with complex rearrangement (if applicable) (%):
104,Indeterminate (explain):
105,EWSR1-ATF1 Fusion (by RT-PCR)
106,No EWSR1-ATF1 fusions detected
107,EWSR1-ATF1 fusions detected
108,Other EWSR1 Fusion (by RT-PCR)
109,No EWSR1 translocation detected
110,EWSR1 translocation detected
112,Fusion partner:
Not set,Mammary Analogue Secretory Carcinoma
113,ETV6 Rearrangements (by FISH)
114,No ETV6 rearrangement detected
115,ETV6 rearrangement detected
116,Indeterminate
117,Percentage of positive cells (%):
118,Percentage of positive cells with classic rearrangement (if applicable) (%):
119,Percentage of positive cells with complex rearrangement (if applicable) (%):
120,Indeterminate (explain):
121,ETV6-NTRK3 Fusion (by RT-PCR)
122,No ETV6-NTRK3 fusions detected
123,ETV6-NTRK3 fusions detected
Not set,Mucoepidermoid Carcinoma
124,MAML2 Rearrangements (by FISH)
125,No MAML2 rearrangement detected
126,MAML2 rearrangement detected
127,Indeterminate
128,Percentage of positive cells (%):
129,Percentage of positive cells with classic rearrangement (if applicable) (%):
130,Percentage of positive cells with complex rearrangement (if applicable) (%):
131,Indeterminate (explain):
132,CRTC1-MAML2 Fusion (by RT-PCR)
133,No CRTC1-MAML2 fusions detected
134,CRTC1-MAML2 fusions detected
135,CRTC3-MAML2 Fusion (by RT-PCR)
136,No CRTC3-MAML2 fusions detected
137,CRTC3-MAML2 fusions detected
Not set,Adenoid Cystic Carcinoma
138,MYB Expression (by IHC)
139,Negative
140,Positive
141,Indeterminate
142,Indeterminate (explain):
143,MYB Rearrangements (by FISH)
144,No MYB rearrangement detected
145,MYB rearrangement detected
146,Indeterminate
147,Percentage of positive cells (%):
148,Percentage of positive cells with classic rearrangement (if applicable) (%):
150,Percentage of positive cells with complex rearrangement (if applicable) (%):
151,Indeterminate (explain):
152,MYB-NFIB Fusion (by FISH)
153,No MYB-NFIB fusions detected
154,MYB-NFIB fusions detected
155,Indeterminate
156,Percentage of positive cells (%):
157,Percentage of positive cells with classic fusion (if applicable) (%):
158,Percentage of positive cells with complex fusion (if applicable) (%):
159,Indeterminate (explain):
160,CRTC1-MAML2 Fusion (by RT-PCR)
161,No CRTC1-MAML2 fusions detected
162,CRTC1-MAML2 fusions detected
Not set,Carcinoma ex Pleomorphic Adenoma/Pleomorphic Adenoma
163,HMGA2 (by FISH)
164,No HMGA2 rearrangement detected
165,HMGA2 rearrangement detected
166,Indeterminate
167,Percentage of positive cells (%):
168,Percentage of positive cells with classic rearrangement (if applicable) (%):
169,Percentage of positive cells with complex rearrangement (if applicable) (%):
170,Indeterminate (explain):
171,CRTC1-MAML2 Fusion (by RT-PCR)
172,Negative
173,Positive
174,Indeterminate
175,Indeterminate (explain):
176,PLAG1 (by FISH)
177,No PLAG1 rearrangement detected
178,PLAG1 rearrangement detected
179,Indeterminate
180,Percentage of positive cells (%):
181,Percentage of positive cells with classic rearrangement (if applicable) (%):
182,Percentage of positive cells with complex rearrangement (if applicable) (%):
183,Indeterminate (explain):
Not set,Salivary Duct Carcinoma
184,Human Epidermal Growth Factor-2 (HER2 [ERBB2]) Expression (by IHC)
185,Negative (score 0)
186,Negative (score 1+)
187,Equivocal (score 2+)
188,Positive (score 3+)
189,Indeterminate
190,Indeterminate (explain):
191,HER2 (ERBB2) Expression (by FISH)
192,Negative (not amplified)
193,Positive (amplified)
194,Indeterminate
195,Indeterminate (explain):
196,Number of observers:
197,Number of invasive cancer cells counted:
198,Assay
199,Using dual-probe assay
200,Using single-probe assay
201,Average number of HER2 (ERBB2) signals per cancer cell:
202,Average number of CEP17 signals per cancer cell:
203,HER2 (ERBB2):CEP17 ratio:
204,Average number of HER2 (ERBB2) signals per cancer cell:
205,Androgen Receptor (by IHC)
206,Negative
207,Positive
208,Indeterminate
209,Indeterminate (explain):
Not set,Sinonasal Malignancies
212,INI-1 (by IHC)
213,Intact (staining retained, negative for INI1 deletion)
214,Lost (staining lost, positive for INI1 alteration)
215,Indeterminate
216,Indeterminate (explain):
Not set,Biphenotypic Sinonasal Sarcoma
217,PAX3 Rearrangements (by FISH)
218,No PAX3 rearrangement detected
219,PAX3 rearrangement detected
220,Percentage of positive cells:
221,Percentage of positive cells with classic rearrangement (if applicable):
222,Percentage of positive cells with complex rearrangement (if applicable):
223,PAX3-MAML3 Fusion (by RT-PCR)
224,No PAX3-MAML3 fusions detected
225,PAX3-MAML3 fusions detected
Not set,Paraganglioma
226,SDHB (by IHC)
227,Intact (staining retained, negative for SDH alteration)
228,Lost (staining lost, positive for SDH alteration)
229,Indeterminate
230,Indeterminate (explain):
231,METHODS
232,Page 1
Not set,Head And Neck Squamous Cell Carcinoma (HNSCC)
233,P16 (by IHC)
271,P16
234,Primary Antibody
235,E6H4
236,Other
237,Other (specify clone):
238,HPV DNA (by ISH)
239,HPV DNA
240,Subtypes Separately Tested
241,High-Risk
242,Low-Risk
243,Specific Subtype
244,High-Risk (specify test/vendor):
245,Low-Risk (specify test/vendor):
246,Specific Subtype:
247,(specify test/vendor):
248,HR-HPV E6/E7 mRNA (by ISH)
249,HR-HPV E6/E7 mRNA (by ISH)
250,HR-HPV E6/E7 mRNA (by ISH) (specify test/vendor):
251,HPV DNA (by PCR)
252,HPV DNA
253,Subtypes Separately Tested
254,High-Risk
255,Low-Risk
256,Specific Subtype
257,High-Risk (specify test/vendor):
258,Low-Risk (specify test/vendor):
259,Specific Subtype:
260,(specify test/vendor):
261,HR-HPV E6/E7 mRNA by RT-PCR
262,HR-HPV E6/E7 mRNA by RT-PCR
263,EBV Testing
264,EBER by ISH
265,EBV DNA by PCR
Not set,NUT Midline Carcinoma
266,NUT Rearrangements
267,Breakapart FISH
268,BRD4-NUT fusion transcript RT-PCR
269,NUT immunohistochemistry
Not set,Salivary Gland Carcinoma
272,EWSR1 Rearrangements
273,Breakapart FISH
274,EWSR1-ATF1 fusion transcript RT-PCR
Not set,Mammary Analogue Secretory Carcinoma
275,ETV6 Rearrangements
276,Breakapart FISH
277,ETV6-NTRK3 fusion transcript RT-PCR
Not set,Mucoepidermoid Carcinoma
278,MAML2 Rearrangements
279,Breakapart FISH
280,CRTC1-MAML2 fusion transcript RT-PCR
281,CRTC3-MAML2 fusion transcript RT-PCR
Not set,Adenoid Cystic Carcinoma
282,MYB Rearrangements
283,Breakapart FISH
284,MYB-NFIB fusion FISH
285,MYB-NFIB fusion transcript RT-PCR
286,MYB immunohistochemistry
Not set,Carcinoma ex Pleomorphic Adenoma/Pleomorphic Adenoma
287,HMGA2
288,Breakapart FISH
289,PLAG1
290,Breakapart FISH
291,PLAG1 Immunohistochemistry
Not set,Salivary Duct Carcinoma
292,Her2 Expression (by IHC)
293,US Food and Drug Administration (FDA) cleared
294,Laboratory-developed test
295,US Food and Drug Administration (FDA) cleared (specify test/vendor):
296,Primary Antibody
297,4B5
298,HercepTest
299,A0485
300,SP3
301,CB11
302,Other
303,Other (specify):
304,HER2 (ERBB2) Expression (by FISH)
305,FDA cleared
306,Laboratory-developed test
307,FDA cleared (specify test/vendor):
308,Laboratory-developed test (specify probe):
309,Androgen receptor immunohistochemistry
310,Androgen receptor immunohistochemistry
Not set,Sinonasal Malignancies
311,Sinonasal Malignancies
312,INI-1
313,PAX-3
Not set,Paraganglioma
314,Paraganglioma
315,SDHB immunohistochemistry
Not set,COMMENT(S)
316,COMMENT(S)
9356,Patient Info
9357,Page 1
Not set,Basic information
9358,Patient name:
9359,Patient family:
9360,Gender
9361,Male
9362,Female
9363,Other
9364,Unknown
9365,Birth date:
9366,Activity:
9367,Active
9368,Inactive
9369,Multiple birth:
9370,True
9371,False
9476,System
9477,Phone
9478,Fax
9479,Email
9480,Pager
9481,Url
9482,Sms
9483,Other
9484,Phone use
9485,Home
9486,Work
9487,Temp
9488,Old
9489,Mobile
9490,Phone
9491,Fax use
9492,Home
9493,Work
9494,Temp
9495,Old
9496,Mobile
9497,Fax
9498,Email use
9499,Home
9500,Work
9501,Temp
9502,Old
9503,Mobile
9504,Email
9505,Pager use
9506,Home
9507,Work
9508,Temp
9509,Old
9510,Mobile
9511,Pager
9512,Url use
9513,Home
9514,Work
9515,Temp
9516,Old
9517,Mobile
9518,Url
9519,Sms use
9520,Home
9521,Work
9522,Temp
9523,Old
9524,Mobile
9525,Sms
9526,Other use
9527,Home
9528,Work
9529,Temp
9530,Old
9531,Mobile
9532,Other
9372,Language:
9373,Serbian
9374,English
9375,Spanish
Not set,Identifiers
9376,Identifier name:
9377,UniqueMasterCitizenNumber
9378,DriverLicence
9379,SocialNumber
9380,Value:
9381,Value:
9382,Value:
Not set,Address information
9383,City:
9384,State:
9385,Postal Code:
9386,Country:
Not set,Contact person information
9387,Name:
9533,System
9534,Phone
9535,Fax
9536,Email
9537,Pager
9538,Url
9539,Sms
9540,Other
9541,Phone use
9542,Home
9543,Work
9544,Temp
9545,Old
9546,Mobile
9547,Phone
9548,Fax use
9549,Home
9550,Work
9551,Temp
9552,Old
9553,Mobile
9554,Fax
9555,Email use
9556,Home
9557,Work
9558,Temp
9559,Old
9560,Mobile
9561,Email
9562,Pager use
9563,Home
9564,Work
9565,Temp
9566,Old
9567,Mobile
9568,Pager
9569,Url use
9570,Home
9571,Work
9572,Temp
9573,Old
9574,Mobile
9575,Url
9576,Sms use
9577,Home
9578,Work
9579,Temp
9580,Old
9581,Mobile
9582,Sms
9583,Other use
9584,Home
9585,Work
9586,Temp
9587,Old
9588,Mobile
9589,Other
9389,City:
9390,State:
9391,Postal Code:
9392,Country:
9393,Gender
9394,Male
9395,Female
9396,Other
9397,Unknown
9398,Relationship:
12345,Protocol for the Examination of Specimens From Patients With Ductal Carcinoma In Situ (DCIS) of the Breast
,
C0007124,DCIS OF THE BREAST
Not set,Specimen Identification
C1321205,Procedure (Note A)
C1292535,Excision (less than total mastectomy)
C0370611,Total mastectomy (including nipple-sparing and skin-sparing mastectomy)
N/A,Other (specify):
,Not specified
,Other (specify)
,Specimen Laterality
,Right
,Left
,Not specified
,Tumor Site (select all that apply)
,Upper outer quadrant
,Lower outer quadrant
,Upper inner quadrant
,Lower inner quadrant
,Central
,Nipple
,Position
,Other
,Not specified
,Position (specify)
,Other (specify)
Not set,Size (Extent) of DCIS (Note C)
,At least
,Additional dimensions
,Number of blocks with DCIS
,Number of blocks examined:
Not set,Histologic Type (Note D)
,
,Ductal carcinoma in situ
Not set,Architectural Patterns (select all that apply) (Note E)
,
,Comedo
,Paget disease (DCIS involving nipple skin)
,Cribriform
,Micropapillary
,Papillary
,Solid
,Other
,Other (specify)
8515,Protocol for the Examination of Specimens From Patients With Cancers of the Larynx
8311,LARYNX (SUPRAGLOTTIS, GLOTTIS, SUBGLOTTIS):
8312,Page 1
Not set,Select a single response unless otherwise indicated.
8313,Procedure (select all that apply)
8314,Excision
8315,Endolaryngeal excision
8316,Transoral laser excision (glottis)
8317,Supraglottic laryngectomy
8318,Supracricoid laryngectomy
8319,Vertical hemilaryngectomy
8320,Partial laryngectomy
8321,Total laryngectomy
8322,Neck (lymph node) dissection
8323,Other
8324,Not specified
8325,Vertical hemilaryngectomy (specify side):
8326,Partial laryngectomy (specify type):
8327,Neck (lymph node) dissection (specify):
8328,Other (specify):
8329,Tumor Site
8330,Larynx, supraglottis
8331,Larynx, glottis
8332,Larynx, subglottis
8333,Other
8334,Not specified
8335,Larynx, supraglottis
8336,Epiglottis, lingual aspect
8337,Epiglottis, laryngeal aspect
8338,Aryepiglottic folds
8339,Arytenoid(s)
8340,False vocal cord
8341,Ventricle
8342,Larynx, glottis
8343,True vocal cord
8344,Anterior commissure
8345,Posterior commissure
8346,With subglottic extension
8347,Other (specify):
8348,Transglottic Extension
8349,Present
8350,Not identified
8351,Tumor Laterality (select all that apply)
8352,Right
8353,Left
8354,Midline
8355,Not specified
8356,Tumor Focality
8357,Unifocal
8358,Multifocal
8359,Cannot be determined
Not set,Tumor Size
8360,Greatest dimension (centimeters):
8361,Additional dimensions (centimeters):
8362,Cannot be determined (explain):
Not set,Histologic Type
8363,Squamous Cell Carcinoma and Variants (select all that apply)
8364,Squamous cell carcinoma, conventional (keratinizing)
8365,Squamous cell carcinoma, nonkeratinizing
8366,Acantholytic squamous cell carcinoma
8367,Adenosquamous carcinoma
8368,Basaloid squamous cell carcinoma
8369,Papillary squamous cell carcinoma
8370,Spindle cell squamous cell carcinoma
8371,Verrucous squamous cell carcinoma
8372,Lymphoepithelial carcinoma
8373,Histologic Grade *
8374,G1: Well differentiated
8375,G2: Moderately differentiated
8376,G3: Poorly differentiated
8377,Other
8378,GX: Cannot be assessed
8379,Other (specify):
8380,Carcinomas of Minor Salivary Glands
8381,Mucoepidermoid carcinoma, low grade
8382,Mucoepidermoid carcinoma, intermediate grade
8383,Mucoepidermoid carcinoma, high grade
8384,Adenoid cystic carcinoma, tubular pattern *
8385,Adenoid cystic carcinoma, cribriform pattern *
8386,Adenoid cystic carcinoma, solid pattern *
8387,Adenocarcinoma, not otherwise specified, low grade
8388,Adenocarcinoma, not otherwise specified, intermediate grade
8389,Adenocarcinoma, not otherwise specified, high grade
8390,Specify percentage of solid component:
8391,Specify percentage of solid component:
8392,Specify percentage of solid component:
8393,Neuroendocrine Carcinoma
8394,Well-differentiated neuroendocrine carcinoma (typical carcinoid tumor)
8395,Moderately differentiated neuroendocrine carcinoma (atypical carcinoid tumor)
8396,Poorly differentiated neuroendocrine carcinoma, small cell type
8397,Poorly differentiated neuroendocrine carcinoma, large cell type
8398,Combined (or composite) neuroendocrine carcinoma with
8399,Mucosal melanoma
8400,Carcinoma, type cannot be determined
8401,Other histologic type not listed
8402,Combined (or composite) neuroendocrine carcinoma with (specify types):
8403,Other histologic type not listed (specify):
Not set,Tumor Extension
8404,Specify:
8405,Margins (select all that apply)
8406,Cannot be assessed
8407,Uninvolved by invasive tumor
8408,Involved by invasive tumor
8409,Uninvolved by high-grade dysplasia/in situ disease *
8410,Involved by high-grade dysplasia/in situ disease *
8411,Distance from closest margin (millimeters):
8412,Specify location of closest margin, per orientation, if possible:
8413,Location and distance of other close margins:
8414,Specify margin(s), per orientation, if possible:
8415,Distance from closest margin (millimeters):
8416,Specify location of closest margin, per orientation, if possible:
8417,Specify margin(s), per orientation, if possible:
8418,Lymphovascular Invasion
8419,Not identified
8420,Present
8421,Cannot be determined
8422,Perineural Invasion
8423,Not identified
8424,Present
8425,Cannot be determined
8426,Regional Lymph Nodes
8427,Lymph nodes submitted or found
8428,Number of Lymph Nodes Involved:
8429,Number cannot be determined (explain):
8430,Number of Lymph Nodes Examined:
8431,Number cannot be determined (explain):
8432,Laterality of Lymph Nodes Involved
8433,Ipsilateral (including midline)
8434,Contralateral
8435,Bilateral
8436,Cannot be determined
8437,Size of Largest Metastatic Deposit (centimeters):
8438,Extranodal Extension (ENE)
8439,Not identified
8440,Present
8441,Cannot be determined
8442,Distance from lymph node capsule (millimeters):
8443,ENEma (>2 mm)
8444,ENEmi (≤2 mm)
Not set,Pathologic Stage Classification (pTNM, AJCC 8th Edition)
8445,TNM Descriptors (select all that apply) *
8446,m (multiple primary tumors)
8447,r (recurrent)
8448,y (posttreatment)
Not set,For All Carcinomas
8449,Primary Tumor (pT)
8450,pTX: Primary tumor cannot be assessed
8451,pTis: Carcinoma in situ
8452,For the Supraglottis
8453,pT1: Tumor limited to one subsite of supraglottis with normal vocal cord mobility
8454,pT2: Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (eg, mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx
8455,pT3: Tumor limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage
8456,pT4 Moderately advanced or very advanced
8457,pT4a: Moderately advanced local disease. Tumor invades through the outer cortex thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of tongue, strap muscles, thyroid, or esophagus)
8458,Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures
8459,For the Glottis
8460,pT1: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility
8461,pT1a: Tumor limited to one vocal cord
8462,pT1b: Tumor involves both vocal cords
8463,pT2: Tumor extends to supraglottis and/or subglottis and/or with impaired vocal cord mobility
8464,pT3: Tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage
8465,pT4: Moderately advanced or very advanced
8466,pT4a: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, cricoid cartilage, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus)
8467,pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures
8468,For the Subglottis
8469,pT1: Tumor limited to subglottis
8470,pT2: Tumor extends to vocal cord(s) with normal or impaired mobility
8471,pT3: Tumor limited to larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage
8472,pT4: Moderately advanced or very advanced
8473,pT4a: Moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus)
8474,pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures
8475,Regional Lymph Nodes (pN) *
8476,pNX: Regional lymph nodes cannot be assessed
8477,pN0: No regional lymph node metastasis
8478,pN1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
8479,pN2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
8480,pN2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)
8481,pN2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−)
8482,pN2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
8483,pN3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+)
8484,pN3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
8485,pN3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+)
8486,Distant Metastasis (pM) *
8487,pM1: Distant metastasis
8488,Specify site(s), if known:
Not set,For Mucosal Melanoma
8489,Primary Tumor (pT)
8490,pT3: Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx
8491,pT4: Moderately advanced or very advanced disease
8492,pT4a: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
8493,pT4b: Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures
8494,Regional Lymph Nodes (pN)
8495,pNX: Regional lymph nodes cannot be assessed
8496,pN0: No regional lymph node metastases
8497,pN1: Regional lymph node metastases present
8498,Distant Metastasis (pM) *
8499,pM1: Distant metastasis present
8500,Specify site(s), if known:
8501,Additional Pathologic Findings (select all that apply)
8502,None identified
8503,Dysplasia, low grade (includes hyperplasia, keratosis, and mild dysplasia)
8504,Dysplasia, high grade (includes moderate to severe dysplasia, and carcinoma in situ)
8505,Squamous papilloma, solitary
8506,Squamous papillomatosis
8507,Inflammation
8508,Squamous metaplasia
8509,Colonization, fungal
8510,Colonization, bacterial
8511,Other
8512,Inflammation (specify type):
8513,Other (specify):
9355,Comment(s)
9356,Patient Info
9357,Page 1
Not set,Basic information
9358,Patient name:
9359,Patient family:
9360,Gender
9361,Male
9362,Female
9363,Other
9364,Unknown
9365,Birth date:
9366,Activity:
9367,Active
9368,Inactive
9369,Multiple birth:
9370,True
9371,False
9476,System
9477,Phone
9478,Fax
9479,Email
9480,Pager
9481,Url
9482,Sms
9483,Other
9484,Phone use
9485,Home
9486,Work
9487,Temp
9488,Old
9489,Mobile
9490,Phone
9491,Fax use
9492,Home
9493,Work
9494,Temp
9495,Old
9496,Mobile
9497,Fax
9498,Email use
9499,Home
9500,Work
9501,Temp
9502,Old
9503,Mobile
9504,Email
9505,Pager use
9506,Home
9507,Work
9508,Temp
9509,Old
9510,Mobile
9511,Pager
9512,Url use
9513,Home
9514,Work
9515,Temp
9516,Old
9517,Mobile
9518,Url
9519,Sms use
9520,Home
9521,Work
9522,Temp
9523,Old
9524,Mobile
9525,Sms
9526,Other use
9527,Home
9528,Work
9529,Temp
9530,Old
9531,Mobile
9532,Other
9372,Language:
9373,Serbian
9374,English
9375,Spanish
Not set,Identifiers
9376,Identifier name:
9377,UniqueMasterCitizenNumber
9378,DriverLicence
9379,SocialNumber
9380,Value:
9381,Value:
9382,Value:
Not set,Address information
9383,City:
9384,State:
9385,Postal Code:
9386,Country:
Not set,Contact person information
9387,Name:
9533,System
9534,Phone
9535,Fax
9536,Email
9537,Pager
9538,Url
9539,Sms
9540,Other
9541,Phone use
9542,Home
9543,Work
9544,Temp
9545,Old
9546,Mobile
9547,Phone
9548,Fax use
9549,Home
9550,Work
9551,Temp
9552,Old
9553,Mobile
9554,Fax
9555,Email use
9556,Home
9557,Work
9558,Temp
9559,Old
9560,Mobile
9561,Email
9562,Pager use
9563,Home
9564,Work
9565,Temp
9566,Old
9567,Mobile
9568,Pager
9569,Url use
9570,Home
9571,Work
9572,Temp
9573,Old
9574,Mobile
9575,Url
9576,Sms use
9577,Home
9578,Work
9579,Temp
9580,Old
9581,Mobile
9582,Sms
9583,Other use
9584,Home
9585,Work
9586,Temp
9587,Old
9588,Mobile
9589,Other
9389,City:
9390,State:
9391,Postal Code:
9392,Country:
9393,Gender
9394,Male
9395,Female
9396,Other
9397,Unknown
9398,Relationship:
,
24,Head and Neck Squamous Cell Carcinoma (HNSCC)
31,Page 1
Not set,Human Papillomavirus (HPV) Testing
33,p16 Expression (by immunohistochemistry) as a Surrogate for Transcriptionally Active High-Risk HPV
34,Negative (<50% diffuse and strong nuclear and cytoplasmic staining) 
35,Equivocal (<70% but >50% diffuse and strong nuclear and cytoplasmic staining)
36,Positive (>70% diffuse and strong nuclear and cytoplasmic staining) 
37,Indeterminate
38,Indeterminate (explain):
39,HPV-DNA (by in situ hybridization [ISH])
40,Negative (no signal)
41,Positive
42,Indeterminate
43,Positive
45,Punctate
46,Diffuse
47,Subtype(s)
48,Indeterminate (explain):
49,Subtype(s) (if available):
50,HPV E6/E7 mRNA (by ISH)
51,Negative (no signal)
52,Positive (cytoplasmic and/or nuclear signals)
53,Indeterminate
54,Subtype(s) (if available):
55,Indeterminate (explain):
56,HPV-DNA (by polymerase chain reaction [PCR])
57,Negative (no signal)
58,Positive
59,Indeterminate
60,Subtype(s) (if available):
61,Indeterminate (explain):
62,HPV E6/E7 mRNA (by reverse transcriptase polymerase chain reaction [RT-PCR])
63,Negative (no signal)
64,Positive
65,Indeterminate
66,Subtype(s) (if available):
67,Indeterminate (explain):
Not set,Epstein-Barr Virus (EBV) Testing
68,EBV Early mRNA (EBER) (by ISH)
69,Negative (no signal)
70,Positive(nuclear signal)
71,Indeterminate
72,Indeterminate (explain):
Not set,NUT Midline Carcinoma
73,NUT Expression (by immunohistochemistry [IHC])
74,Negative
75,Positive
76,Indeterminate
78,Indeterminate (explain):
79,NUT Rearrangements (by Fluorescence ISH [FISH])
80,No NUT rearrangement detected
81,NUT rearrangement detected
82,Percentage of positive cells (%):
83,Percentage of positive cells with classic rearrangement (if applicable) (%):
84,Percentage of positive cells with complex rearrangement (if applicable) (%):
85,BRD4-NUT Fusion (by RT-PCR)
86,No BRD4-NUT fusions detected
87,BRD4-NUT fusions detected
89,Other NUT Fusion (by RT-PCR)
90,No NUT translocation detected
91,NUT translocation detected
93,Fusion partner:
95,Salivary Gland Carcinoma
96,Page 1
Not set,(Hyalinizing) Clear Cell Carcinoma
97,EWSR1 Rearrangements (by FISH)
98,No EWSR1 rearrangement detected
99,EWSR1 rearrangement detected
100,Indeterminate
101,Percentage of positive cells (%):
102,Percentage of positive cells with classic rearrangement (if applicable) (%):
103,Percentage of positive cells with complex rearrangement (if applicable) (%):
104,Indeterminate (explain):
105,EWSR1-ATF1 Fusion (by RT-PCR)
106,No EWSR1-ATF1 fusions detected
107,EWSR1-ATF1 fusions detected
108,Other EWSR1 Fusion (by RT-PCR)
109,No EWSR1 translocation detected
110,EWSR1 translocation detected
112,Fusion partner:
Not set,Mammary Analogue Secretory Carcinoma
113,ETV6 Rearrangements (by FISH)
114,No ETV6 rearrangement detected
115,ETV6 rearrangement detected
116,Indeterminate
117,Percentage of positive cells (%):
118,Percentage of positive cells with classic rearrangement (if applicable) (%):
119,Percentage of positive cells with complex rearrangement (if applicable) (%):
120,Indeterminate (explain):
121,ETV6-NTRK3 Fusion (by RT-PCR)
122,No ETV6-NTRK3 fusions detected
123,ETV6-NTRK3 fusions detected
Not set,Mucoepidermoid Carcinoma
124,MAML2 Rearrangements (by FISH)
125,No MAML2 rearrangement detected
126,MAML2 rearrangement detected
127,Indeterminate
128,Percentage of positive cells (%):
129,Percentage of positive cells with classic rearrangement (if applicable) (%):
130,Percentage of positive cells with complex rearrangement (if applicable) (%):
131,Indeterminate (explain):
132,CRTC1-MAML2 Fusion (by RT-PCR)
133,No CRTC1-MAML2 fusions detected
314,CRTC1-MAML2 fusions detected
135,CRTC3-MAML2 Fusion (by RT-PCR)
136,No CRTC3-MAML2 fusions detected
137,CRTC3-MAML2 fusions detected
Not set,Adenoid Cystic Carcinoma
138,MYB Expression (by IHC)
139,Negative
140,Positive
141,Indeterminate
142,Indeterminate (explain):
143,MYB Rearrangements (by FISH)
144,No MYB rearrangement detected
145,MYB rearrangement detected
146,Indeterminate
147,Percentage of positive cells (%):
148,Percentage of positive cells with classic rearrangement (if applicable) (%):
150,Percentage of positive cells with complex rearrangement (if applicable) (%):
151,Indeterminate (explain):
152,MYB-NFIB Fusion (by FISH)
153,No MYB-NFIB fusions detected
154,MYB-NFIB fusions detected
155,Indeterminate
156,Percentage of positive cells (%):
157,Percentage of positive cells with classic fusion (if applicable) (%):
158,Percentage of positive cells with complex fusion (if applicable) (%):
159,Indeterminate (explain):
160,CRTC1-MAML2 Fusion (by RT-PCR)
161,No CRTC1-MAML2 fusions detected
162,CRTC1-MAML2 fusions detected
Not set,Carcinoma ex Pleomorphic Adenoma/Pleomorphic Adenoma
163,HMGA2 (by FISH)
164,No HMGA2 rearrangement detected
165,HMGA2 rearrangement detected
166,Indeterminate
167,Percentage of positive cells (%):
168,Percentage of positive cells with classic rearrangement (if applicable) (%):
169,Percentage of positive cells with complex rearrangement (if applicable) (%):
170,Indeterminate (explain):
171,CRTC1-MAML2 Fusion (by RT-PCR)
172,Negative
173,Positive
174,Indeterminate
175,Indeterminate (explain):
176,PLAG1 (by FISH)
177,No PLAG1 rearrangement detected
178,PLAG1 rearrangement detected
179,Indeterminate
180,Percentage of positive cells (%):
181,Percentage of positive cells with classic rearrangement (if applicable) (%):
182,Percentage of positive cells with complex rearrangement (if applicable) (%):
183,Indeterminate (explain):
Not set,Salivary Duct Carcinoma
184,Human Epidermal Growth Factor-2 (HER2 [ERBB2]) Expression (by IHC)
185,Negative (score 0)
186,Negative (score 1+)
187,Equivocal (score 2+)
188,Positive (score 3+)
189,Indeterminate
190,Indeterminate (explain):
191,HER2 (ERBB2) Expression (by FISH)
192,Negative (not amplified)
193,Positive (amplified)
194,Indeterminate
195,Indeterminate (explain):
196,Number of observers:
197,Number of invasive cancer cells counted:
198,Assay
199,Using dual-probe assay
200,Using single-probe assay
201,Average number of HER2 (ERBB2) signals per cancer cell:
202,Average number of CEP17 signals per cancer cell:
203,HER2 (ERBB2):CEP17 ratio:
204,Average number of HER2 (ERBB2) signals per cancer cell:
205,Androgen Receptor (by IHC)
206,Negative
207,Positive
208,Indeterminate
209,Indeterminate (explain):
210,Sinonasal Malignancies
211,Page 1
Not set,INI-Deficient Sinonasal Carcinoma/Rhabdoid Tumor
212,INI-1 (by IHC)
213,Intact (staining retained, negative for INI1 deletion)
214,Lost (staining lost, positive for INI1 alteration)
215,Indeterminate
216,Indeterminate (explain):
Not set,Biphenotypic Sinonasal Sarcoma
217,PAX3 Rearrangements (by FISH)
218,No PAX3 rearrangement detected
219,PAX3 rearrangement detected
220,Percentage of positive cells:
221,Percentage of positive cells with classic rearrangement (if applicable):
222,Percentage of positive cells with complex rearrangement (if applicable):
223,PAX3-MAML3 Fusion (by RT-PCR)
224,No PAX3-MAML3 fusions detected
225,PAX3-MAML3 fusions detected
Not set,Paraganglioma
226,SDHB (by IHC)
227,Intact (staining retained, negative for SDH alteration)
228,Lost (staining lost, positive for SDH alteration)
229,Indeterminate
230,Indeterminate (explain):
231,Head And Neck Squamous Cell Carcinoma (HNSCC)
232,Page 1
Not set,HPV Testing
233,P16 (by IHC)
232,P16
234,Primary Antibody
235,E6H4
236,Other
237,Other (specify clone):
238,HPV DNA (by ISH)
239,HPV DNA
240,Subtypes Separately Tested
241,High-Risk
242,Low-Risk
243,Specific Subtype
244,High-Risk (specify test/vendor):
245,Low-Risk (specify test/vendor):
246,Specific Subtype:
247,(specify test/vendor):
248,HR-HPV E6/E7 mRNA (by ISH)
249,HR-HPV E6/E7 mRNA (by ISH)
250,HR-HPV E6/E7 mRNA (by ISH) (specify test/vendor):
251,HPV DNA (by PCR)
252,HPV DNA
253,Subtypes Separately Tested
254,High-Risk
255,Low-Risk
256,Specific Subtype
257,High-Risk (specify test/vendor):
258,Low-Risk (specify test/vendor):
259,Specific Subtype:
260,(specify test/vendor):
261,HR-HPV E6/E7 mRNA by RT-PCR
262,HR-HPV E6/E7 mRNA by RT-PCR
263,EBV Testing
264,EBER by ISH
265,EBV DNA by PCR
Not set,NUT Midline Carcinoma
266,NUT Rearrangements
267,Breakapart FISH
268,BRD4-NUT fusion transcript RT-PCR
269,NUT immunohistochemistry
270,Salivary Gland Carcinoma
271,Page 1
Not set,(Hyalinizing) Clear Cell Carcinoma
272,EWSR1 Rearrangements
273,Breakapart FISH
274,EWSR1-ATF1 fusion transcript RT-PCR
Not set,Mammary Analogue Secretory Carcinoma
275,ETV6 Rearrangements
276,Breakapart FISH
277,ETV6-NTRK3 fusion transcript RT-PCR
Not set,Mucoepidermoid Carcinoma
278,MAML2 Rearrangements
279,Breakapart FISH
280,CRTC1-MAML2 fusion transcript RT-PCR
281,CRTC3-MAML2 fusion transcript RT-PCR
Not set,Adenoid Cystic Carcinoma
282,MYB Rearrangements
283,Breakapart FISH
284,MYB-NFIB fusion FISH
285,MYB-NFIB fusion transcript RT-PCR
286,MYB immunohistochemistry
Not set,Carcinoma ex Pleomorphic Adenoma/Pleomorphic Adenoma
287,HMGA2
288,Breakapart FISH
289,PLAG1
290,Breakapart FISH
291,PLAG1 Immunohistochemistry
Not set,Salivary Duct Carcinoma
292,Her2 Expression (by IHC)
293,US Food and Drug Administration (FDA) cleared
294,Laboratory-developed test
295,US Food and Drug Administration (FDA) cleared (specify test/vendor):
296,Primary Antibody
297,4B5
298,HercepTest
299,A0485
300,SP3
301,CB11
302,Other
303,Other (specify):
304,HER2 (ERBB2) Expression (by FISH)
305,FDA cleared
306,Laboratory-developed test
307,FDA cleared (specify test/vendor):
308,Laboratory-developed test (specify probe):
309,Androgen receptor immunohistochemistry
310,Androgen receptor immunohistochemistry
Not set,Sinonasal Malignancies
311,Sinonasal Malignancies
312,INI-1
313,PAX-3
Not set,Paraganglioma
314,Paraganglioma
315,SDHB immunohistochemistry
Not set,COMMENT(S)
316,COMMENT(S)
8516,Protocol for the Examination of Specimens from Patients with Cancers of the Lip and Oral Cavity
8517,LIP AND ORAL CAVITY:
8518,Page 1
Not set,Select a single response unless otherwise indicated.
8519,Procedure (select all that apply)
8520,Excision
8521,Glossectomy
8522,Buccal mucosal resection
8523,Mandibulectomy
8524,Maxillectomy
8525,Palatectomy
8526,Neck (lymph node) dissection
8527,Other
8528,Not specified
8529,Glossectomy (specify):
8530,Buccal mucosal resection (specify):
8531,Mandibulectomy (specify):
8532,Maxillectomy (specify):
8533,Neck (lymph node) dissection (specify):
8534,Other (specify):
8535,Tumor Site
8536,Lip
8537,Oral
8538,Other
8539,Not specified
8540,Lip
8541,Mucosa of upper lip
8542,Ventral surface of tongue
8543,Oral
8544,Lateral border of tongue
8545,Ventral surface of tongue
8546,Dorsal surface of tongue
8547,Anterior two-thirds of tongue
8548,Upper gingiva
8549,Lower gingiva
8550,Anterior floor of mouth
8551,Floor of mouth
8552,Hard palate
8553,Buccal mucosa
8554,Vestibule of mouth, maxillary
8555,Vestibule of mouth, mandibular
8556,Alveolar process, maxillary
8557,Alveolar process, mandibular
8558,Retromolar area
8559,Other (specify):
8560,Tumor Laterality (select all that apply)
8561,Right
8562,Left
8563,Midline
8564,Not specified
8565,Tumor Focality
8566,Unifocal
8567,Multifocal
8568,Cannot be determined
Not set,Tumor Size
8569,Greatest dimension (centimeters):
8570,Additional dimensions (centimeters):
8571,Cannot be determined (explain):
8572,Tumor Depth of Invasion (DOI) (millimeters):
Not set,Histologic Type
8573,Squamous Cell Carcinoma and Variants (select all that apply)
8574,Squamous cell carcinoma, conventional
8575,Acantholytic squamous cell carcinoma
8576,Adenosquamous carcinoma
8577,Basaloid squamous cell carcinoma
8578,Carcinoma cuniculatum
8579,Papillary squamous cell carcinoma
8580,Spindle cell squamous cell carcinoma
8581,Verrucous squamous cell carcinoma
8582,Lymphoepithelial carcinoma
8583,Carcinomas of Minor Salivary Glands
8584,Mucoepidermoid carcinoma, low grade
8585,Mucoepidermoid carcinoma, intermediate grade
8586,Mucoepidermoid carcinoma, high grade
8587,Adenoid cystic carcinoma, tubular pattern *
8588,Adenoid cystic carcinoma, cribriform pattern *
8589,Adenoid cystic carcinoma, solid pattern *
8590,Acinic cell carcinoma
8591,Polymorphous adenocarcinoma, classic, low grade
8592,Polymorphous adenocarcinoma, classic, intermediate grade
8593,Polymorphous adenocarcinoma, classic, high grade
8594,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), low grade
8595,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), intermediate grade
8596,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), high grade
8597,(Mammary analogue) Secretory carcinoma
8598,Salivary duct carcinoma
8599,Epithelial-myoepithelial carcinoma
8600,(Hyalinizing) clear cell carcinoma
8601,Adenocarcinoma, not otherwise specified, low grade
8602,Adenocarcinoma, not otherwise specified, intermediate grade
8603,Adenocarcinoma, not otherwise specified, high grade
8604,Basal cell adenocarcinoma
8605,Carcinosarcoma (true malignant mixed tumor)
8606,Intraductal carcinoma, low grade
8607,Intraductal carcinoma, high grade
8608,Myoepithelial carcinoma
8609,Oncocytic carcinoma
8610,Specify percentage of solid component:
8611,Specify percentage of solid component:
8612,Specify percentage of solid component:
8613,Preexisting pleomorphic adenoma component *
8614,Carcinoma ex pleomorphic adenoma, minimally invasive
8615,Carcinoma ex pleomorphic adenoma, invasive
8616,Carcinoma ex pleomorphic adenoma, intracapsular (noninvasive)
8617,Neuroendocrine Carcinoma
8618,Well differentiated neuroendocrine carcinoma (typical carcinoid tumor)
8619,Moderately differentiated neuroendocrine carcinoma (atypical carcinoid tumor)
8620,Poorly differentiated neuroendocrine carcinoma, small cell type
8621,Poorly differentiated neuroendocrine carcinoma, large cell type
8622,Combined (or composite) neuroendocrine carcinoma
8623,Mucosal melanoma
8624,Carcinoma, type cannot be determined
8625,Other histologic type not listed
8626,Combined (or composite) neuroendocrine carcinoma (specify types):
8627,Other histologic type not listed (specify):
8628,Histologic Grade *
8629,G1: Well differentiated
8630,G2: Moderately differentiated
8631,G3: Poorly differentiated
8632,Other
8633,GX: Cannot be assessed
8634,Other (specify):
Not set,Tumor Extension
8635,Specify:
8636,Specimen Margins (select all that apply)
8637,Cannot be assessed
8638,Uninvolved by invasive tumor
8639,Involved by invasive tumor
8640,Uninvolved by high-grade dysplasia/in situ disease *
8641,Involved by high-grade dysplasia/in situ disease *
8642,Distance from closest margin (millimeters):
8643,Specify location of closest margin, per orientation, if possible:
8644,Location and distance of other close margins:
8645,Specify margin(s), per orientation, if possible:
8646,Distance from closest margin (millimeters):
8647,Specify location of closest margin, per orientation, if possible:
8648,Specify margin(s), per orientation, if possible:
8649,Tumor Bed (Separately Submitted) Margin Orientation *
8650,Oriented to true margin surface
8651,Unoriented to true margin surface
8652,Tumor Bed (Separately Submitted) Margins (select all that apply) *
8653,Uninvolved by invasive tumor
8654,Involved by invasive tumor
8655,Uninvolved by high-grade dysplasia/in situ disease *
8656,Involved by high-grade dysplasia/in situ disease *
8657,Specify distance to true margin surface (millimeters):
8658,Specify margin(s), per part labeling, if possible:
8659,Specify distance to true margin surface (millimeters):
8660,Specify margin(s), per orientation, if possible:
8661,Lymphovascular Invasion
8662,Not identified
8663,Present
8664,Cannot be determined
8665,Perineural Invasion
8666,Not identified
8667,Present
8668,Cannot be determined
8669,Extent of perineural invasion (specify):
8670,Worst Pattern of Invasion (WPOI)
8671,WPOI 5
8672,WPOI 1-4
8673,Regional Lymph Nodes
8674,Lymph nodes submitted or found
8675,Number of Lymph Nodes Involved:
8676,Number cannot be determined (explain):
8677,Number of Lymph Nodes Examined:
8678,Number cannot be determined (explain):
8679,Laterality of Lymph Nodes Involved
8680,Ipsilateral (including midline)
8681,Contralateral
8682,Bilateral
8683,Cannot be determined
8684,Size of Largest Metastatic Deposit (centimeters):
8685,Extranodal Extension (ENE)
8686,Not identified
8687,Present
8688,Cannot be determined
8689,Distance from lymph node capsule (millimeters):
8690,ENEma (>2 mm)
8691,ENEmi (≤2 mm)
Not set,Pathologic Stage Classification (pTNM, AJCC 8th Edition)
8692,TNM Descriptors (select all that apply) *
8693,m (multiple primary tumors)
8694,r (recurrent)
8695,y (posttreatment)
Not set,For All Carcinomas
8696,Primary Tumor (pT)
8697,pTX: Primary tumor cannot be assessed
8698,pTis: Carcinoma in situ
8699,pT1: Tumor ≤2 cm with depth of invasion (DOI) ≤5 mm
8700,pT2: Tumor ≤2 cm with DOI >5 mm or tumor >2 cm and ≤4 cm with DOI ≤10 mm
8701,pT3: Tumor >2 cm and ≤4 cm with DOI >10 mm or tumor >4 cm with DOI ≤10 mm
8702,pT4: Moderately advanced or very advanced local disease
8703,pT4a: Moderately advanced local disease. Tumor >4 cm with DOI >10 mm or tumor invades adjacent structures only (eg, through cortical bone of the mandible or maxilla or involves the maxillary sinus or skin of the face)
8704,pT4b: Very advanced local disease. Tumor invades masticator space, pterygoid plates, or skull base, and/or encases the internal carotid artery
8705,Regional Lymph Nodes (pN) *
8706,pNX: Regional lymph nodes cannot be assessed
8707,pN0: No regional lymph node metastasis
8708,pN1: pN1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(−)
8709,pN2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
8710,pN2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)
8711,pN2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−)
8712,pN2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
8713,pN3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)
8714,pN3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
8715,pN3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)
8716,Distant Metastasis (pM) *
8717,pM1: Distant metastasis
8718,Specify site(s), if known:
Not set,For Mucosal Melanoma
8719,Primary Tumor (pT)
8720,pT3: Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx
8721,pT4: Moderately advanced or very advanced disease
8722,pT4a: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
8723,pT4b: Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures
8724,Regional Lymph Nodes (pN)
8725,pNX: Regional lymph nodes cannot be assessed
8726,pN0: No regional lymph node metastases
8727,pN1: Regional lymph node metastases present
8728,Distant Metastasis (pM) *
8729,pM1: Distant metastasis present
8730,Specify site(s), if known:
8731,Additional Pathologic Findings (select all that apply)
8732,None identified
8733,Keratinizing dysplasia, mild
8734,Keratinizing dysplasia, moderate
8735,Keratinizing dysplasia, severe (carcinoma in situ)
8736,Nonkeratinizing dysplasia, mild
8737,Nonkeratinizing dysplasia, moderate
8738,Nonkeratinizing dysplasia, severe (carcinoma in situ)
8739,Inflammation
8740,Epithelial hyperplasia
8741,Colonization, fungal
8742,Colonization, bacterial
8743,Other
8744,Inflammation (specify type):
8745,Other (specify):
Not set,COMMENT(S)
8746,COMMENT(S)
9356,Patient Info
9357,Page 1
Not set,Basic information
9358,Patient name:
9359,Patient family:
9360,Gender
9361,Male
9362,Female
9363,Other
9364,Unknown
9365,Birth date:
9366,Activity:
9367,Active
9368,Inactive
9369,Multiple birth:
9370,True
9371,False
9476,System
9477,Phone
9478,Fax
9479,Email
9480,Pager
9481,Url
9482,Sms
9483,Other
9484,Phone use
9485,Home
9486,Work
9487,Temp
9488,Old
9489,Mobile
9490,Phone
9491,Fax use
9492,Home
9493,Work
9494,Temp
9495,Old
9496,Mobile
9497,Fax
9498,Email use
9499,Home
9500,Work
9501,Temp
9502,Old
9503,Mobile
9504,Email
9505,Pager use
9506,Home
9507,Work
9508,Temp
9509,Old
9510,Mobile
9511,Pager
9512,Url use
9513,Home
9514,Work
9515,Temp
9516,Old
9517,Mobile
9518,Url
9519,Sms use
9520,Home
9521,Work
9522,Temp
9523,Old
9524,Mobile
9525,Sms
9526,Other use
9527,Home
9528,Work
9529,Temp
9530,Old
9531,Mobile
9532,Other
9372,Language:
9373,Serbian
9374,English
9375,Spanish
Not set,Identifiers
9376,Identifier name:
9377,UniqueMasterCitizenNumber
9378,DriverLicence
9379,SocialNumber
9380,Value:
9381,Value:
9382,Value:
Not set,Address information
9383,City:
9384,State:
9385,Postal Code:
9386,Country:
Not set,Contact person information
9387,Name:
9533,System
9534,Phone
9535,Fax
9536,Email
9537,Pager
9538,Url
9539,Sms
9540,Other
9541,Phone use
9542,Home
9543,Work
9544,Temp
9545,Old
9546,Mobile
9547,Phone
9548,Fax use
9549,Home
9550,Work
9551,Temp
9552,Old
9553,Mobile
9554,Fax
9555,Email use
9556,Home
9557,Work
9558,Temp
9559,Old
9560,Mobile
9561,Email
9562,Pager use
9563,Home
9564,Work
9565,Temp
9566,Old
9567,Mobile
9568,Pager
9569,Url use
9570,Home
9571,Work
9572,Temp
9573,Old
9574,Mobile
9575,Url
9576,Sms use
9577,Home
9578,Work
9579,Temp
9580,Old
9581,Mobile
9582,Sms
9583,Other use
9584,Home
9585,Work
9586,Temp
9587,Old
9588,Mobile
9589,Other
9389,City:
9390,State:
9391,Postal Code:
9392,Country:
9393,Gender
9394,Male
9395,Female
9396,Other
9397,Unknown
9398,Relationship:
8750,Protocol for the Examination of Specimens From Patients With Carcinomas of the Major Salivary Glands
8751,MAJOR SALIVARY GLANDS:
8752,Page 1
Not set,Select a single response unless otherwise indicated.
8753,Procedure (select all that apply)
8754,Excision
8755,Parotidectomy, superficial
8756,Parotidectomy, deep
8757,Parotidectomy, total
8758,Parotidectomy, not specified
8759,Resection, submandibular gland
8760,Resection, sublingual gland
8761,Neck (lymph node) dissection
8762,Other
8763,Not specified
8764,Neck (lymph node) dissection (specify):
8765,Other (specify):
8766,Tumor Site
8767,Parotid gland
8768,Submandibular gland
8769,Sublingual gland
8770,Other
8771,Not specified
8772,Parotid gland
8773,Superficial lobe
8774,Deep lobe
8775,Entire parotid gland
8776,Other (specify):
8777,Tumor Laterality
8778,Right
8779,Left
8780,Bilateral
8781,Not specified
8782,Tumor Focality
8783,Unifocal
8784,Multifocal
8785,Cannot be determined
Not set,Tumor Size
8786,Greatest dimension (centimeters):
8787,Additional dimensions (centimeters):
8789,Cannot be determined (explain):
8790,Histologic Type
8791,Mucoepidermoid carcinoma, low grade
8792,Mucoepidermoid carcinoma, intermediate grade
8793,Mucoepidermoid carcinoma, high grade
8794,Adenoid cystic carcinoma, tubular pattern *
8795,Adenoid cystic carcinoma, cribriform pattern *
8796,Adenoid cystic carcinoma, solid pattern *
8797,Acinic cell carcinoma
8798,Polymorphous adenocarcinoma, classic, low grade
8799,Polymorphous adenocarcinoma, classic, intermediate grade
8800,Polymorphous adenocarcinoma, classic, high grade
8801,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), low grade
8802,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), intermediate grade
8803,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), high grade
8804,(Mammary analogue) Secretory carcinoma
8805,Salivary duct carcinoma
8806,Epithelial-myoepithelial carcinoma
8807,(Hyalinizing) clear cell carcinoma
8808,Adenocarcinoma, not otherwise specified, low grade
8809,Adenocarcinoma, not otherwise specified, intermediate grade
8810,Adenocarcinoma, not otherwise specified, high grade
8811,Basal cell adenocarcinoma
8812,Carcinosarcoma (true malignant mixed tumor)
8813,Intraductal carcinoma, low grade
8814,Intraductal carcinoma, high grade
8815,Lymphoepithelial carcinoma
8816,Myoepithelial carcinoma
8817,Oncocytic carcinoma
8818,Poorly differentiated carcinoma, small cell neuroendocrine
8819,Poorly differentiated carcinoma, large cell neuroendocrine
8820,Poorly differentiated carcinoma, undifferentiated
8821,Sebaceous adenocarcinoma
8822,Squamous cell carcinoma, primary
8823,Specify percentage of solid component:
8824,Specify percentage of solid component:
8825,Specify percentage of solid component:
8826,Preexisting pleomorphic adenoma component *
8827,Carcinoma ex pleomorphic adenoma, minimally invasive
8828,Carcinoma ex pleomorphic adenoma, invasive
8829,Carcinoma ex pleomorphic adenoma, intracapsular (noninvasive)
8830,Carcinoma, type cannot be determined
8831,Other histologic type not listed
8832,Other histologic type not listed (specify):
8833,High-Grade Transformation (if applicable)
8834,Present
8835,Not identified
Not set,Tumor Extension
8836,Macroscopic Tumor Extension (specify):
8837,Margins
8838,Cannot be assessed
8839,Uninvolved by carcinoma
8840,Involved by carcinoma
8841,Distance of tumor from closest margin (millimeters):
8842,Specify margin, if possible:
8843,Specify margin(s), if possible:
8844,Lymphovascular Invasion
8845,Not identified
8846,Present
8847,Cannot be determined
8848,Perineural Invasion
8849,Not identified
8850,Present
8851,Cannot be determined
8852,Regional Lymph Nodes
8853,Lymph nodes submitted or found
8854,Number of Lymph Nodes Involved:
8855,Number cannot be determined (explain):
8856,Number of Lymph Nodes Examined:
8857,Number cannot be determined (explain):
8858,Laterality of Lymph Nodes Involved
8859,Ipsilateral (including midline)
8860,Contralateral
8861,Bilateral
8862,Cannot be determined
8863,Size of Largest Metastatic Deposit (centimeters):
8864,Extranodal Extension (ENE)
8865,Not identified
8866,Present
8867,Cannot be determined
8868,Distance from lymph node capsule (millimeters):
8869,ENEma (>2 mm)
8870,ENEmi (≤2 mm)
Not set,Pathologic Stage Classification (pTNM, AJCC 8th Edition)
8871,TNM Descriptors (select all that apply) *
8872,m (multiple primary tumors)
8873,r (recurrent)
8874,y (posttreatment)
8875,Primary Tumor (pT)
8876,pTX: Primary tumor cannot be assessed
8877,pT0: No evidence of primary tumor
8878,pTis: Carcinoma in situ
8879,pT1: Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension *
8880,pT2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension *
8881,pT3: Tumor larger than 4 cm and/or tumor having extraparenchymal extension *
8882,pT4: Moderately advanced or very advanced disease
8883,pT4a: Moderately advanced disease. Tumor invades skin, mandible, ear canal, and/or facial nerve.
8884,pT4b: Very advanced disease. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery
8885,Regional Lymph Nodes (pN) *
8886,pNX: Regional lymph nodes cannot be assessed
8887,pN0: No regional lymph node metastasis
8888,pN1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
8889,pN2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
8890,pN2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)
8891,pN2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−)
8892,pN2c: Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)
8893,pN3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)
8894,pN3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
8895,pN3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)
8896,Distant Metastasis (pM) *
8897,pM1: Distant metastasis
8898,Specify site(s), if known:
8899,Additional Pathologic Findings (select all that apply)
8900,Sialadenitis
8901,Tumor associated lymphoid proliferation (TALP)
8902,Other
8903,Other (specify):
8904,Comment(s)
9356,Patient Info
9357,Page 1
Not set,Basic information
9358,Patient name:
9359,Patient family:
9360,Gender
9361,Male
9362,Female
9363,Other
9364,Unknown
9365,Birth date:
9366,Activity:
9367,Active
9368,Inactive
9369,Multiple birth:
9370,True
9371,False
9476,System
9477,Phone
9478,Fax
9479,Email
9480,Pager
9481,Url
9482,Sms
9483,Other
9484,Phone use
9485,Home
9486,Work
9487,Temp
9488,Old
9489,Mobile
9490,Phone
9491,Fax use
9492,Home
9493,Work
9494,Temp
9495,Old
9496,Mobile
9497,Fax
9498,Email use
9499,Home
9500,Work
9501,Temp
9502,Old
9503,Mobile
9504,Email
9505,Pager use
9506,Home
9507,Work
9508,Temp
9509,Old
9510,Mobile
9511,Pager
9512,Url use
9513,Home
9514,Work
9515,Temp
9516,Old
9517,Mobile
9518,Url
9519,Sms use
9520,Home
9521,Work
9522,Temp
9523,Old
9524,Mobile
9525,Sms
9526,Other use
9527,Home
9528,Work
9529,Temp
9530,Old
9531,Mobile
9532,Other
9372,Language:
9373,Serbian
9374,English
9375,Spanish
Not set,Identifiers
9376,Identifier name:
9377,UniqueMasterCitizenNumber
9378,DriverLicence
9379,SocialNumber
9380,Value:
9381,Value:
9382,Value:
Not set,Address information
9383,City:
9384,State:
9385,Postal Code:
9386,Country:
Not set,Contact person information
9387,Name:
9533,System
9534,Phone
9535,Fax
9536,Email
9537,Pager
9538,Url
9539,Sms
9540,Other
9541,Phone use
9542,Home
9543,Work
9544,Temp
9545,Old
9546,Mobile
9547,Phone
9548,Fax use
9549,Home
9550,Work
9551,Temp
9552,Old
9553,Mobile
9554,Fax
9555,Email use
9556,Home
9557,Work
9558,Temp
9559,Old
9560,Mobile
9561,Email
9562,Pager use
9563,Home
9564,Work
9565,Temp
9566,Old
9567,Mobile
9568,Pager
9569,Url use
9570,Home
9571,Work
9572,Temp
9573,Old
9574,Mobile
9575,Url
9576,Sms use
9577,Home
9578,Work
9579,Temp
9580,Old
9581,Mobile
9582,Sms
9583,Other use
9584,Home
9585,Work
9586,Temp
9587,Old
9588,Mobile
9589,Other
9389,City:
9390,State:
9391,Postal Code:
9392,Country:
9393,Gender
9394,Male
9395,Female
9396,Other
9397,Unknown
9398,Relationship:
8905,Protocol for the Examination of Specimens From Patients With Cancers of the Nasal Cavity and Paranasal Sinuses
8906,NASAL CAVITY AND PARANASAL SINUSES:
8907,Page 1
Not set,Select a single response unless otherwise indicated.
8908,Procedure (select all that apply)
8909,Excision
8910,Partial maxillectomy
8911,Radical maxillectomy
8912,Neck (lymph node) dissection
8913,Other
8914,Not specified
8915,Neck (lymph node) dissection (specify):
8916,Other (specify):
8917,Tumor Site (select all that apply)
8918,Nasal septum
8919,Nasal floor
8920,Nasal lateral wall
8921,Nasal vestibule
8922,Nasal cavity, not otherwise specified
8923,Paranasal sinus(es), maxillary
8924,Paranasal sinus(es), ethmoid
8925,Paranasal sinus(es), frontal
8926,Paranasal sinus(es), sphenoid
8927,Other
8928,Not specified
8929,Other (specify):
8930,Tumor Laterality (select all that apply)
8931,Right
8932,Left
8933,Midline
8934,Not specified
8935,Tumor Focality
8936,Unifocal
8937,Multifocal
8938,Cannot be determined
Not set,Tumor Size
8939,Greatest dimension (centimeters):
8940,Additional dimensions (centimeters):
8941,Cannot be determined (explain):
Not set,Histologic Type
8942,Squamous Cell Carcinoma and Variants (select all that apply)
8943,Squamous cell carcinoma, keratinizing
8944,Squamous cell carcinoma, nonkeratinizing
8945,Adenosquamous carcinoma
8946,Basaloid squamous cell carcinoma
8947,Papillary squamous cell carcinoma
8948,Spindle cell squamous cell carcinoma
8949,Verrucous squamous cell carcinoma
8950,Lymphoepithelial carcinoma (non-nasopharyngeal)
8951,Sinonasal undifferentiated carcinoma (SNUC)
8952,NUT carcinoma
8953,Adenocarcinoma, Non-Salivary Gland Type
8954,Intestinal adenocarcinoma, papillary pattern
8955,Intestinal adenocarcinoma, colonic pattern
8956,Intestinal adenocarcinoma, solid pattern
8957,Intestinal adenocarcinoma, mucinous pattern
8958,Intestinal adenocarcinoma, mixed pattern
8959,Non-intestinal adenocarcinoma, low grade
8960,Non-intestinal adenocarcinoma, intermediate grade
8961,Non-intestinal adenocarcinoma, high grade
8962,Carcinomas of Minor Salivary Glands
8963,Mucoepidermoid carcinoma, low grade
8964,Mucoepidermoid carcinoma, intermediate grade
8965,Mucoepidermoid carcinoma, high grade
8966,Adenoid cystic carcinoma, tubular pattern *
8967,Adenoid cystic carcinoma, cribriform pattern *
8968,Adenoid cystic carcinoma, solid pattern *
8969,Acinic cell carcinoma
8970,Polymorphous adenocarcinoma, classic, low grade
8971,Polymorphous adenocarcinoma, classic, intermediate grade
8972,Polymorphous adenocarcinoma, classic, high grade
8973,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), low grade
8974,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), intermediate grade
8975,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), high grade
8976,(Mammary analogue) Secretory carcinoma
8977,Salivary duct carcinoma
8978,Epithelial-myoepithelial carcinoma
8979,(Hyalinizing) clear cell carcinoma
8980,Adenocarcinoma, not otherwise specified, low grade
8981,Adenocarcinoma, not otherwise specified, intermediate grade
8982,Adenocarcinoma, not otherwise specified, high grade
8983,Specify percentage of solid component:
8984,Specify percentage of solid component:
8985,Specify percentage of solid component:
8986,Preexisting pleomorphic adenoma component *
8987,Carcinoma ex pleomorphic adenoma, minimally invasive
8988,Carcinoma ex pleomorphic adenoma, invasive
8989,Carcinoma ex pleomorphic adenoma, intracapsular (noninvasive)
8990,Neuroendocrine Carcinoma
8991,Well-differentiated neuroendocrine carcinoma (typical carcinoid tumor)
8992,Moderately differentiated neuroendocrine carcinoma (atypical carcinoid tumor)
8993,Poorly differentiated neuroendocrine carcinoma, small cell type
8994,Poorly differentiated neuroendocrine carcinoma, large cell type
8995,Combined (or composite) neuroendocrine carcinoma with
8996,Mucosal melanoma
8997,Carcinoma, type cannot be determined
8998,Other histologic type not listed
8999,Combined (or composite) neuroendocrine carcinoma with (specify types):
9000,Other histologic type not listed (specify):
9001,Histologic Grade *
9002,G1: Well differentiated
9003,G2: Moderately differentiated
9004,G3: Poorly differentiated
9005,Other
9006,GX: Cannot be assessed
9007,Other (specify):
Not set,Tumor Extension
9008,Specify:
9009,Margins (select all that apply)
9010,Cannot be assessed
9011,Uninvolved by invasive tumor
9012,Involved by invasive tumor
9013,Uninvolved by high grade dysplasia/in situ disease *
9014,Involved by high grade dysplasia/in situ disease *
9015,Distance from closest margin (millimeters):
9016,Specify location of closest margin, per orientation, if possible:
9017,Location and distance of other close margins:
9018,Specify margin(s), per orientation, if possible:
9019,Distance from closest margin (millimeters):
9020,Specify location of closest margin, per orientation, if possible:
9021,Specify margin(s), per orientation, if possible:
9022,Lymphovascular Invasion
9023,Not identified
9024,Present
9025,Cannot be determined
9026,Perineural Invasion
9027,Not identified
9028,Present
9029,Cannot be determined
9030,Regional Lymph Nodes
9031,Lymph nodes submitted or found
9032,Number of Lymph Nodes Involved:
9033,Number cannot be determined (explain):
9034,Number of Lymph Nodes Examined:
9035,Number cannot be determined (explain):
9036,Laterality of Lymph Nodes Involved
9037,Ipsilateral (including midline)
9038,Contralateral
9039,Bilateral
9040,Cannot be determined
9041,Size of Largest Metastatic Deposit (centimeters):
9042,Extranodal Extension (ENE)
9043,Not identified
9044,Present
9045,Cannot be determined
9046,Distance from lymph node capsule (millimeters):
9047,ENEma (>2 mm)
9048,ENEmi (≤2 mm)
Not set,Pathologic Stage Classification (pTNM, AJCC 8th Edition)
9049,TNM Descriptors (select all that apply) *
9050,m (multiple primary tumors)
9051,r (recurrent)
9052,y (posttreatment)
Not set,For All Carcinomas
9053,Primary Tumor (pT)
9054,pTX: Primary tumor cannot be assessed
9055,pTis: Carcinoma in situ
9056,For the Maxillary Sinus
9057,pT1: Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone
9058,pT2: pT2: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates
9059,pT3: Tumor invades any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses
9060,pT4: Moderately advanced or very advanced local diseased
9061,pT4a: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses
9062,pT4b: Very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus
9063,For the Nasal Cavity and Ethmoid Sinus
9064,pT1: Tumor restricted to any one subsite, with or without bone invasion
9065,pT2: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with our without bony invasion
9066,pT3: Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate
9067,pT4: Moderately advanced or very advanced local disease
9068,pT4a: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses
9069,pT4b: Very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus
9070,Regional Lymph Nodes (pN)
9071,pNX: Regional lymph nodes cannot be assessed
9072,pN0: No regional lymph node metastasis
9073,pN1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
9074,pN2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
9075,pN2a: Metastasis in single ipsilateral node 3 cm or less in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)
9076,pN2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−)
9077,pN2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
9078,pN3: Metastases in a lymph node larger than 6 cm in greatest dimension and ENE(−); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)
9079,pN3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
9080,pN3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)
9081,Distant Metastasis (pM) *
9082,pM1: Distant metastasis
9083,Specify site(s), if known:
Not set,For Mucosal Melanoma
9084,Primary Tumor (pT)
9085,pT3: Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx
9086,pT4: Moderately advanced or very advanced disease
9087,pT4a: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
9088,pT4b: Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures
9089,Regional Lymph Nodes (pN)
9090,pNX: Regional lymph nodes cannot be assessed
9091,pN0: No regional lymph node metastases
9092,pN1: Regional lymph node metastases present
9093,Distant Metastasis (pM) *
9094,pM1: Distant metastasis present
9095,Specify site(s), if known:
9096,Additional Pathologic Findings (select all that apply)
9097,None identified
9098,Carcinoma in situ
9099,Epithelial dysplasia
9100,Sinonasal papilloma
9101,Inflammation
9102,Squamous metaplasia
9103,Epithelial hyperplasia
9104,Colonization, fungal
9105,Colonization, bacterial
9106,Other
9107,Epithelial dysplasia (specify type):
9108,Sinonasal papilloma (specify type):
9109,Inflammation (specify type):
9110,Other (specify):
9111,Comment(s)
9356,Patient Info
9357,Page 1
Not set,Basic information
9358,Patient name:
9359,Patient family:
9360,Gender
9361,Male
9362,Female
9363,Other
9364,Unknown
9365,Birth date:
9366,Activity:
9367,Active
9368,Inactive
9369,Multiple birth:
9370,True
9371,False
9476,System
9477,Phone
9478,Fax
9479,Email
9480,Pager
9481,Url
9482,Sms
9483,Other
9484,Phone use
9485,Home
9486,Work
9487,Temp
9488,Old
9489,Mobile
9490,Phone
9491,Fax use
9492,Home
9493,Work
9494,Temp
9495,Old
9496,Mobile
9497,Fax
9498,Email use
9499,Home
9500,Work
9501,Temp
9502,Old
9503,Mobile
9504,Email
9505,Pager use
9506,Home
9507,Work
9508,Temp
9509,Old
9510,Mobile
9511,Pager
9512,Url use
9513,Home
9514,Work
9515,Temp
9516,Old
9517,Mobile
9518,Url
9519,Sms use
9520,Home
9521,Work
9522,Temp
9523,Old
9524,Mobile
9525,Sms
9526,Other use
9527,Home
9528,Work
9529,Temp
9530,Old
9531,Mobile
9532,Other
9372,Language:
9373,Serbian
9374,English
9375,Spanish
Not set,Identifiers
9376,Identifier name:
9377,UniqueMasterCitizenNumber
9378,DriverLicence
9379,SocialNumber
9380,Value:
9381,Value:
9382,Value:
Not set,Address information
9383,City:
9384,State:
9385,Postal Code:
9386,Country:
Not set,Contact person information
9387,Name:
9533,System
9534,Phone
9535,Fax
9536,Email
9537,Pager
9538,Url
9539,Sms
9540,Other
9541,Phone use
9542,Home
9543,Work
9544,Temp
9545,Old
9546,Mobile
9547,Phone
9548,Fax use
9549,Home
9550,Work
9551,Temp
9552,Old
9553,Mobile
9554,Fax
9555,Email use
9556,Home
9557,Work
9558,Temp
9559,Old
9560,Mobile
9561,Email
9562,Pager use
9563,Home
9564,Work
9565,Temp
9566,Old
9567,Mobile
9568,Pager
9569,Url use
9570,Home
9571,Work
9572,Temp
9573,Old
9574,Mobile
9575,Url
9576,Sms use
9577,Home
9578,Work
9579,Temp
9580,Old
9581,Mobile
9582,Sms
9583,Other use
9584,Home
9585,Work
9586,Temp
9587,Old
9588,Mobile
9589,Other
9389,City:
9390,State:
9391,Postal Code:
9392,Country:
9393,Gender
9394,Male
9395,Female
9396,Other
9397,Unknown
9398,Relationship:
9112,Protocol for the Examination of Specimens From Patients With Cancers of the Pharynx
9113,PHARYNX (OROPHARYNX, HYPOPHARYNX, NASOPHARYNX):
9114,Page 1
Not set,Select a single response unless otherwise indicated.
9115,Procedure (select all that apply)
9116,Excision
9117,Tonsillectomy
9118,Laryngopharyngectomy
9119,Neck (lymph node) dissection
9120,Other
9121,Not specified
9122,Neck (lymph node) dissection (specify):
9123,Other (specify):
9124,Tumor Site *
9125,Oropharynx
9126,Nasopharynx
9127,Hypopharynx
9128,Other
9129,Not specified
9130,Oropharynx
9131,Palatine tonsil
9132,Base of tongue, including lingual tonsil
9133,Soft palate
9134,Uvula
9135,Pharyngeal wall (posterior)
9136,Nasopharynx
9137,Nasopharyngeal tonsils (adenoids)
9138,Hypopharynx
9139,Piriform sinus
9140,Postcricoid
9141,Pharyngeal wall (posterior and/or lateral)
9142,Other (specify):
9143,Tumor Laterality (select all that apply)
9144,Left
9145,Right
9146,Midline
9147,Not specified
9148,Tumor Focality
9149,Unifocal
9150,Multifocal
9151,Cannot be determined
Not set,Tumor Size
9152,Greatest dimension (centimeters):
9153,Additional dimensions (centimeters):
9154,Cannot be determined (explain):
Not set,Histologic Type
9155,Carcinomas of the Oropharynx and Hypopharynx
9156,Human papillomavirus (HPV)-mediated (positive) squamous cell carcinoma (oropharynx only)
9157,HPV-unrelated (negative) squamous cell carcinoma (oropharynx)
9158,Oropharyngeal squamous cell carcinoma, HPV status unknown (see “ancillary studies” for additional notes)
9159,Hypopharyngeal squamous cell carcinoma
9160,Squamous Cell Carcinoma and Variants (select all that apply)
9161,Squamous cell carcinoma, conventional (keratinizing)
9162,Squamous cell carcinoma, nonkeratinizing
9163,Acantholytic squamous cell carcinoma
9164,Adenosquamous carcinoma
9165,Basaloid squamous cell carcinoma
9166,Papillary squamous cell carcinoma
9167,Spindle cell squamous cell carcinoma
9168,Verrucous squamous cell carcinoma
9169,Lymphoepithelial carcinoma (non-nasopharyngeal)
9170,Carcinomas of the Nasopharynx
9171,Keratinizing squamous cell carcinoma
9172,Nonkeratinizing squamous cell carcinoma
9173,Basaloid squamous cell carcinoma
9174,Carcinomas of Minor Salivary Glands
9175,Mucoepidermoid carcinoma, low grade
9176,Mucoepidermoid carcinoma, intermediate grade
9177,Mucoepidermoid carcinoma, high grade
9178,Adenoid cystic carcinoma, tubular pattern *
9179,Adenoid cystic carcinoma, cribriform pattern *
9180,Adenoid cystic carcinoma, solid pattern *
9181,Acinic cell carcinoma
9182,Polymorphous adenocarcinoma, classic, low grade
9183,Polymorphous adenocarcinoma, classic, intermediate grade
9184,Polymorphous adenocarcinoma, classic, high grade
9185,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), low grade
9186,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), intermediate grade
9187,Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), high grade
9188,(Mammary analogue) Secretory carcinoma
9189,Salivary duct carcinoma
9190,Epithelial-myoepithelial carcinoma
9191,(Hyalinizing) clear cell carcinoma
9192,Adenocarcinoma, not otherwise specified, low grade
9193,Adenocarcinoma, not otherwise specified, intermediate grade
9194,Adenocarcinoma, not otherwise specified, high grade
9195,Basal cell adenocarcinoma
9196,Carcinosarcoma (true malignant mixed tumor)
9197,Intraductal carcinoma, low grade
9198,Intraductal carcinoma, high grade
9199,Lymphoepithelial carcinoma
9200,Myoepithelial carcinoma
9201,Oncocytic carcinoma
9202,Specify percentage of solid component:
9203,Specify percentage of solid component:
9204,Specify percentage of solid component:
9205,Preexisting pleomorphic adenoma component *
9206,Carcinoma ex pleomorphic adenoma, minimally invasive
9207,Carcinoma ex pleomorphic adenoma, invasive
9208,Carcinoma ex pleomorphic adenoma, intracapsular (noninvasive)
9209,Adenocarcinomas (Non-Salivary Gland Type)
9210,Nasopharyngeal papillary adenocarcinoma
9211,Neuroendocrine Carcinoma
9212,Small cell neuroendocrine carcinoma, HPV negative
9213,Small cell neuroendocrine carcinoma, HPV positive
9214,Large cell neuroendocrine carcinoma, HPV negative
9215,Large cell neuroendocrine carcinoma, HPV positive
9216,Mucosal melanoma
9217,Carcinoma, type cannot be determined
9218,Other histologic type not listed
9219,Other histologic type not listed (specify):
9220,Histologic Grade *
9221,G1: Well differentiated
9222,G2: Moderately differentiated
9223,G3: Poorly differentiated
9224,Other
9225,GX: Cannot be assessed
9226,Other (specify):
Not set,Tumor Extension
9227,Specify:
9228,Margins (select all that apply)
9229,Cannot be assessed
9230,Uninvolved by invasive tumor
9231,Involved by invasive tumor
9232,Uninvolved by high grade dysplasia/in situ disease *
9233,Involved by high grade dysplasia/in situ disease *
9234,Distance from closest margin (millimeters):
9235,Specify location of closest margin, per orientation, if possible:
9236,Location and distance of other close margins:
9237,Specify margin(s), per orientation, if possible:
9238,Distance from closest margin (millimeters):
9239,Specify location of closest margin, per orientation, if possible:
9240,Specify margin(s), per orientation, if possible:
9241,Lymphovascular Invasion
9242,Not identified
9243,Present
9244,Cannot be determined
9245,Perineural Invasion
9246,Not identified
9247,Present
9248,Cannot be determined
9249,Regional Lymph Nodes
9250,Lymph nodes submitted or found
9251,Number of Lymph Nodes Involved:
9252,Number of Lymph Nodes Examined:
9253,Laterality of Lymph Nodes Involved
9254,Ipsilateral (including midline)
9255,Contralateral
9256,Bilateral
9257,Cannot be determined
9258,Size of Largest Metastatic Deposit (centimeters):
9259,Extranodal Extension (ENE) *
9260,Not identified
9261,Present
9262,Cannot be determined
9263,Distance from lymph node capsule (millimeters):
9264,ENEma (>2 mm)
9265,ENEmi (≤2 mm)
Not set,Pathologic Stage Classification (pTNM, AJCC 8th Edition)
9266,TNM Descriptors (select all that apply) *
9267,m (multiple primary tumors)
9268,r (recurrent)
9269,y (posttreatment)
Not set,For All Carcinomas
9270,Primary Tumor (pT)
9271,pT0: No primary identified
9272,pT1: Tumor 2 cm or smaller in greatest dimension
9273,pT2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension
9274,pT3: Tumor more than 4 cm in greatest dimension or extension to lingual surface of epiglottis
9275,pT4: Moderately advanced local disease. Tumor invades larynx, extrinsic muscle of tongue, medial pterygoid muscles, hard palate, or mandible or beyond *
9276,For HPV-Unrelated (Negative) Oropharynx
9277,pTX: Primary tumor cannot be assessed
9278,pTis: Carcinoma in situ
9279,pT1: Tumor 2 cm or smaller in greatest dimension
9280,pT2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension
9281,pT3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis
9282,pT4: Moderately advanced or very advanced local disease
9283,pT4a: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible *
9284,pT4b: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery
9285,For Nasopharynx
9286,pTX: Primary tumor cannot be assessed
9287,pT0: No tumor identified, but EBV-positive cervical node(s) involvement
9288,pT1: Tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without parapharyngeal involvement
9289,pT2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles)
9290,pT3: Tumor with infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses
9291,pT4: Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle
9292,For Hypopharynx
9293,pTX: Primary tumor cannot be assessed
9294,pTis: Carcinoma in situ
9295,pT1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension
9296,pT2: Tumor invades more than one subsite of hypopharynx or an adjacent site, or measures larger than 2 cm but not larger than 4 cm in greatest dimension without fixation of hemilarynx
9297,pT3: Tumor measures larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophageal mucosa.
9298,pT4: Moderately advanced and very advanced local disease
9299,pT4a: Moderately advanced local disease. Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, esophageal muscle or central compartment soft tissue.
9300,pT4b: Very advanced local disease. Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.
9301,Regional Lymph Nodes (pN)
9302,pNX: Regional lymph nodes cannot be assessed
9303,pN0: No regional lymph node metastasis
9304,pN1: Metastasis in 4 or fewer lymph nodes
9305,pN2: Metastasis in more than 4 lymph nodes
9306,For HPV-Unrelated (Negative) Oropharynx and Hypopharynx *
9307,pNX: Regional lymph nodes cannot be assessed
9308,pN0: No regional lymph node metastasis
9309,pN1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(−)
9310,pN2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
9311,pN2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)
9312,pN2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−)
9313,pN2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
9314,pN3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)
9315,pN3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
9316,pN3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)
9317,For Nasopharynx
9318,pNX: Regional lymph nodes cannot be assessed
9319,pN0: No regional lymph node metastasis
9320,pN1: Unilateral metastasis in cervical lymph node(s) and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
9321,pN2: Bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
9322,pN3: Unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage
9323,Distant Metastasis (pM) *
9324,pM1: Distant metastasis
9325,Specify site(s), if known:
Not set,For Mucosal Melanoma
9326,Primary Tumor (pT)
9327,pT3: Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx
9328,pT4: Moderately advanced or very advanced disease
9329,pT4a: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
9330,pT4b: Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures
9331,Regional Lymph Nodes (pN)
9332,pNX: Regional lymph nodes cannot be assessed
9333,pN0: No regional lymph node metastases
9334,pN1: Regional lymph node metastases present
9335,Distant Metastasis (pM) *
9336,pM1: Distant metastasis present
9337,Specify site(s), if known:
9338,Additional Pathologic Findings (select all that apply)
9339,None identified
9340,Keratinizing dysplasia, mild *
9341,Keratinizing dysplasia, moderate *
9342,Keratinizing dysplasia, severe (carcinoma in situ) *
9343,Nonkeratinizing dysplasia, mild *
9344,Nonkeratinizing dysplasia, moderate *
9345,Nonkeratinizing dysplasia, severe (carcinoma in situ) *
9346,Inflammation
9347,Squamous metaplasia
9348,Epithelial hyperplasia
9349,Colonization, fungal
9350,Colonization, bacterial
9351,Other
9352,Inflammation (specify type):
9353,Other (specify):
9354,Comment(s)
9356,Patient Info
9357,Page 1
Not set,Basic information
9358,Patient name:
9359,Patient family:
9360,Gender
9361,Male
9362,Female
9363,Other
9364,Unknown
9365,Birth date:
9366,Activity:
9367,Active
9368,Inactive
9369,Multiple birth:
9370,True
9371,False
9476,System
9477,Phone
9478,Fax
9479,Email
9480,Pager
9481,Url
9482,Sms
9483,Other
9484,Phone use
9485,Home
9486,Work
9487,Temp
9488,Old
9489,Mobile
9490,Phone
9491,Fax use
9492,Home
9493,Work
9494,Temp
9495,Old
9496,Mobile
9497,Fax
9498,Email use
9499,Home
9500,Work
9501,Temp
9502,Old
9503,Mobile
9504,Email
9505,Pager use
9506,Home
9507,Work
9508,Temp
9509,Old
9510,Mobile
9511,Pager
9512,Url use
9513,Home
9514,Work
9515,Temp
9516,Old
9517,Mobile
9518,Url
9519,Sms use
9520,Home
9521,Work
9522,Temp
9523,Old
9524,Mobile
9525,Sms
9526,Other use
9527,Home
9528,Work
9529,Temp
9530,Old
9531,Mobile
9532,Other
9372,Language:
9373,Serbian
9374,English
9375,Spanish
Not set,Identifiers
9376,Identifier name:
9377,UniqueMasterCitizenNumber
9378,DriverLicence
9379,SocialNumber
9380,Value:
9381,Value:
9382,Value:
Not set,Address information
9383,City:
9384,State:
9385,Postal Code:
9386,Country:
Not set,Contact person information
9387,Name:
9533,System
9534,Phone
9535,Fax
9536,Email
9537,Pager
9538,Url
9539,Sms
9540,Other
9541,Phone use
9542,Home
9543,Work
9544,Temp
9545,Old
9546,Mobile
9547,Phone
9548,Fax use
9549,Home
9550,Work
9551,Temp
9552,Old
9553,Mobile
9554,Fax
9555,Email use
9556,Home
9557,Work
9558,Temp
9559,Old
9560,Mobile
9561,Email
9562,Pager use
9563,Home
9564,Work
9565,Temp
9566,Old
9567,Mobile
9568,Pager
9569,Url use
9570,Home
9571,Work
9572,Temp
9573,Old
9574,Mobile
9575,Url
9576,Sms use
9577,Home
9578,Work
9579,Temp
9580,Old
9581,Mobile
9582,Sms
9583,Other use
9584,Home
9585,Work
9586,Temp
9587,Old
9588,Mobile
9589,Other
9389,City:
9390,State:
9391,Postal Code:
9392,Country:
9393,Gender
9394,Male
9395,Female
9396,Other
9397,Unknown
9398,Relationship:
9399,CT NECK WITHOUT CONTRAST
9400,CT NECK WITHOUT CONTRAST
9401,Page 1
Not set,HISTORY:
9402,Patient age
9403,Patient gender
9404,Indication for CT
9405,neck pain
9406,neck mass
Not set,TECHNIQUE:
9407,CTDI (mGy):
9408,DLP (mGy-cm):
9409,COMPARISON:
Not set,FINDINGS:
9410,PHARYNGEAL MUCOSA:
9411,ORAL CAVITY:
9412,LARYNX:
9413,LYMPH NODES:
9414,SALIVARY GLANDS:
9415,THYROID:
9416,VESSELS AND CAROTID SPACE:
9417,BONES:
9418,OTHER:
9419,IMPRESSION:
9420,MRI NECK WITHOUT AND WITH CONTRAST
9421,MRI NECK WITHOUT AND WITH CONTRAST
9422,Page 1
Not set,HISTORY:
9423,Patient age
9424,Patient gender
9425,Indication for CT
Not set,TECHNIQUE:
9426,MR images of the neck were acquired without and with Gadavist intravenous contrast. (mL)
9427,COMPARISON:
Not set,FINDINGS:
9428,PHARYNGEAL MUCOSA:
9429,ORAL CAVITY:
9430,LARYNX:
9431,LYMPH NODES:
9432,SALIVARY GLANDS:
9433,THYROID:
9434,FLOW VOIDS AND CAROTID SPACE:
9435,BONES:
9436,OTHER:
9437,IMPRESSION:
9438,MRI TEMPOROMANDIBULAR JOINTS WITHOUT CONTRAST
9439,MRI TEMPOROMANDIBULAR JOINTS WITHOUT CONTRAST
9440,Page 1
Not set,HISTORY:
9441,Patient age
9442,Patient gender
9443,Indication for CT
9444,jaw pain
9445,Other
9446,Other
Not set,TECHNIQUE:
9447,COMPARISON:
9448,None available.
9449,Other
9450,Other
Not set,FINDINGS - RIGHT TMJ:
9451,MANDIBULAR CONDYLE:
9452,Normal morphology and signal. Condyle is well seated within the mandibular fossa on the closed-mouth view and appropriately translates to the level of the articular eminence on the open-mouth view.
9453,Other
9454,Other
9455,ARTICULAR DISC:
9456,Normal position in closed and open mouth positions with normal capturing. Normal signal and bowtie morphology.
9457,Other
9458,Other
Not set,FINDINGS - LEFT TMJ:
9459,MANDIBULAR CONDYLE:
9460,Normal morphology and signal. Condyle is well seated within the mandibular fossa on the closed-mouth view and appropriately translates to the level of the articular eminence on the open-mouth view.
9461,Other
9462,Other
9463,ARTICULAR DISC:
9464,Normal position in closed and open mouth positions with normal capturing. Normal signal and bowtie morphology.
9465,Other
9466,Other
9468,OTHER:
9469,None
9470,Other
9471,Other
9472,IMPRESSION:
9473,Normal MRI temporomandibular joints.
9474,Other
9475,Other
,CBCT Maxillofacial Region
9590,CT Abdomen & Pelvis w Contrast
9591,MRI TEMPOROMANDIBULAR JOINTS WITHOUT CONTRAST
9592,Page 1
Not set,Procedure Information
9593,Technique:
9594,Helical images were obtained through the abdomen and pelvis following the protocol administration of nonionic intravenous contrast material and positive oral contrast material. No complications were reported.
9595,Helical images were obtained through the abdomen and pelvis following the protocol administration of nonionic intravenous contrast material. Since no oral contrast was administered, the sensitivity of this exam for evaluating the bowels, retroperitoneum, and any potential intraabdominal fluid collections is limited. No complications were reported
9596,Helical images were obtained through the abdomen and pelvis following the protocol administration of positive oral contrast material. IV contrast was not administered, limiting the sensitivity of this exam for solid visceral organs, vascular structures, and retroperitoneum. No complications were reported.
9597,Were late arterial phase image obtained?
9598,Because of the provided clinical history late arterial ('pancreatic') phase images were obtained in addition to the standard portal venous phase images.
9599,Because of the provided clinical history, late arterial and 5 minute delayed images were obtained in addition to the standard portal venous phase images.
9600,Becaused of the provided clincal history, late arterial phase images were obtained in addition to the standard portal venous phase images.
9601,Contrast material delivery was optimized for assessment of the arterial system, thus limiting evaluation of the solid visceral organs and venous structures.
Not set,Clinical Information
9602,Indication:
9603,Comparison:
Not set,Findings
9604,Liver:
9605,Gallbladder and Bile Ducts:
9606,Kidneys:
9607,Adrenals:
9608,Spleen:
9609,Pancreas:
9610,Bowel and Stomach:
9611,Appendix:
9612,Pelvis:
9613,The prostate and seminal vesicles are unremarkable.
9614,The uterus is unremarkable. No abnormal adnexal masses.
9615,The prostate is enlarged, a nonspecific finding but one that is typically secondary to BPH.
9616,The uterus is not visualized, consistent with a hysterectomy. No abnormal adnexal masses.
9617,Mesentery/Peritoneum:
9618,Nodes:
9619,Vasculature:
9620,Bone Windows:
9621,Fluid:
9622,Lung windows through the lung bases:
9623,Normal.
9624,Please see separately dictated but concurrently performed thoracic CT.
9625,Soft tissues:
9626,Other findings:
9627,Impression
9628,CT Chest wo Contrast
9629,CT Chest wo Contrast
9630,Page 1
Not set,Procedure Information
9631,Technique:
Not set,Clinical Information
9632,Indication:
9633,Comparison:
Not set,Findings
9634,Pulmonary Parenchyma and Airways:
9635,Pleural Space:
9636,Heart and Pericardium:
9637,Mediastinum and Hila:
9638,Thoracic Vessels:
9639,Osseous Structures and Chest Wall:
9640,Upper Abdomen:
9641,No pathologic process is present in the imaged portion of the upper abdomen.
9642,Imaging findings in the abdomen and pelvis are reported separately.
9643,Additional findings:
9644,Impression
9645,CT Neck
9646,CT Neck
9647,Page 1
Not set,CT Neck
9648,CT Neck
Not set,Clinical information
9649,Clinical information
9650,Comparison:
Not set,Findings
9651,Orbits, paranasal sinuses, and skull base:
9652,Nasopharynx:
9653,Suprahyoid neck:
9654,Infrahyoid neck:
9655,Thyroid:
9656,Thoracic inlet:
9657,Lymph nodes
9658,Vascular structures:
9659,Other findings:
9660,Impression
9661,Paranasal Sinuses
9662,Paranasal Sinuses
9663,Page 1
Not set,Paranasal Sinuses
9664,Paranasal Sinuses
9665,Clinical information
9666,Comparison
9667,Findings
9668,Impression
9669,Parathyroid SPECT
9670,Parathyroid SPECT
9671,Page 1
Not set,Parathyroid SPECT
9672,Parathyroid SPECT
9673,Dose (mCi)
9674,Clinical information
9675,Comparison
Not set,Findings
9676,Thyroid tracer washout:
9677,Parathyroid uptake:
9678,Normal uptake:
9679,Impression:
9680,PET-CT Oncologic
9681,PET-CT Oncologic Study
9682,Page 1
Not set,PET-CT Oncologic Study
9683,Duration of fast prior to injection:
9684,Blood glucose prior to injection (mg/dl):
9685,Scan region:
9686,Radiopharmaceutical:
9687,Radiopharmaceutical (mCi IV):
9688,Calibration time:
9689,Administration time:
9690,Injection site:
9691,Post-injection imaging delay (minutes):
9692,Attenuation correction:
9693,Clinical information
9694,Comparison
Not set,Findings - Neck
9695,Hypermetabolic foci:
9696,Present of visible lymphadenopathy or tumor mass?
Not set,Findings - Thorax
9697,Hypermetabolic foci:
9698,Heart and great vessels:
9699,Adenopathy:
9700,Pleural or pericardial effusion:
9701,Lungs:
Not set,Findings - Abdomen
9702,Hypermetabolic foci:
9703,Liver:
9704,Gallbladder:
9705,Spleen:
9706,Pancreas:
9707,Great abdominal vessels
9708,Kidneys:
9709,Anterior abdominal wall:
9710,Hypermetabolic lymph nodes:
Not set,Findings - Pelvis
9711,Hypermetabolic foci:
9712,Anterior and inner pelvic walls:
9713,Pelvic viscera:
9714,Infradiaphragmatic free air:
9715,Free pelvic fluid:
9716,Hypermetabolic lymph nodes:
Not set,Findings - Bones
9717,Hypermetabolic foci:
9718,Presence of lytic or blastic foci?
9719,Impression
9720,EORTC response criteria:
9721,Complete Metabolic Response. MaxSUV < 2.5 or equivalent to background
9722,Partial Metabolic Response. Decrease in MaxSUV >= 25%
9723,Progressive Metabolic Disease. Increase in MaxSUV > 25%
9724,Stable Metabolic Disease. Change in MaxSUV < 25%
9725,Primary tumor response WHO category:
9726,CR - No radiologically detectable residual tumor
9727,PR - At least 30% decrease in longest recordable dimension of tumor
9728,PD - At least 20% increase in longest recordable dimension of tumor
9729,NC - No change
